Merus N.V. (MRUS) Sees Path to Registration for Zenocutuzumab in 1H22 - Roth Capital
Tweet Send to a Friend
Roth Capital analyst Tony Butler reiterated a Buy rating and $32.00 price target on Merus N.V. (NASDAQ: MRUS) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
